Prevention and Treatment of Diabetic Retinopathy: Evidence from Clinical trials and Perspectives

Current Diabetes Reviews

Volumn 7, Issue 3, 2011, Pages 190-200

  Abbate, Manuela ^a   Cravedi, Paolo ^a   Iliev, Ilian ^a   Remuzzi, Giuseppe ^a   Ruggenenti, Piero ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Anti VEGF agents; Diabetic retinopathy; Fenofibrates; Glycemic control; Renin angiotensin system; Statins

Indexed keywords

ACETYLSALICYLIC ACID; BEVACIZUMAB; ENALAPRIL; FENOFIBRATE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NISOLDIPINE; PEGAPTANIB; RANIBIZUMAB; ROSIGLITAZONE; TRANDOLAPRIL; TRANDOLAPRIL PLUS VERAPAMIL; TRIACYLGLYCEROL; VASCULOTROPIN;

ARTICLE; BLEEDING; BLINDNESS; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DRUG FATALITY; DYSLIPIDEMIA; GLYCEMIC CONTROL; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; VISUAL ACUITY; VISUAL IMPAIRMENT; WESTERN HEMISPHERE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS; DIABETIC RETINOPATHY; DYSLIPIDEMIAS; ENDOCRINOLOGY; EVIDENCE-BASED PRACTICE; HUMANS; HYPERGLYCEMIA; HYPERTENSION; RENIN-ANGIOTENSIN SYSTEM;

EID: 79959344912     PISSN: 15733998     EISSN: 18756417     Source Type: Journal    
DOI: 10.2174/157339911795843168     Document Type: Article

References (134)

1. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. IX. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1989; 107(2): 237-43.
2. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984; 102(4): 527-32.
3. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27(5): 1047-53.
4. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998; 21(4): 518-24.
5. Coughlan A, McCarty DJ, Jorgensen LN, Zimmet P. The epidemic of NIDDM in Asian and Pacific Island populations: prevalence and risk factors. Horm Metab Res 1997; 29(7): 323-31.
6. Bouchardat A. Nouveau mémoire sur la glycosurie. Ann de Thérap 1846, Suppl P: 162-311.
7. Noyes; HD. Retinitis in glycosuria. Trans Am Ophthalmol Soc 1868; 1(4-5): 71-5.
8. Nettleship E. On oedema or cystic disease of the retina. Roy Ophthalmol Lond Hosp Rep 1872; VII: 343-51.
9. Mackenzie S, Nettleship E. A case of glycosuric retinitis. Roy Ophth Lond Hosp Rep 1877; IX: 134.
10. Ballantyne AJ, Loewensstein A. Exudates in diabetic retinopathy. Trans Ophthalmol Soc UK 1943; 63: 95.
11. Meyer-Schwickerath G. Koagulation der Netzhaut mit Sonnenlicht. Berl Dtsch Ophthalmol Ges 1950; 55: 256-9.
12. The Diabetes Control and Complication Trail Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329(14): 977-86.
13. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321(7258): 405-12.
14. Stratton IM, Kohner EM, Aldington SJ, et al. UKPDS 50: risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis. Diabetologia 2001; 44(2): 156-63.
15. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984; 102(4): 520-6.
16. Wilkinson CP, Ferris FL 3rd, Klein RE, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 2003; 110(9): 1677-82.
17. Fong DS, Aiello L, Gardner TW, et al. Retinopathy in diabetes. Diabetes Care 2004; 27(Suppl 1): S84-7.
18. Viswanath K, McGavin DD. Diabetic retinopathy: clinical findings and management. Community Eye Health 2003; 16(46): 21-4.
19. Klein R, Klein BE, Magli YL, et al. An alternative method of grading diabetic retinopathy. Ophthalmology 1986; 93(9): 1183-7.
20. Sheetz MJ, King GL. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA 2002; 288(20): 2579-88.
21. American Diabetes Association. Standards of medical care in diabetes--2011. Diabetes Care 2011; 34 (Suppl 1): S11-61.
22. Wong TY, Liew G, Tapp RJ, et al. Relation between fasting glucose and retinopathy for diagnosis of diabetes: three populationbased cross-sectional studies. Lancet 2008; 371(9614): 736-43.
23. Buell C, Kermah D, Davidson MB. Utility of A1C for diabetes screening in the 1999 2004 NHANES population. Diabetes Care 2007; 30(9): 2233-5.
24. Cheng YJ, Gregg EW, Geiss LS, et al. Association of A1C and fasting plasma glucose levels with diabetic retinopathy prevalence in the U.S. population: implications for diabetes diagnostic thresholds. Diabetes Care 2009; 32(11): 2027-32.
25. Wang PH, Lau J, Chalmers TC. Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. Lancet 1993; 341(8856): 1306-9.
26. Davis MD, Fisher MR, Gangnon RE, et al. Risk factors for highrisk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. Invest Ophthalmol Vis Sci 1998; 39(2): 233-52.
27. White NH, Sun W, Cleary PA, et al. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Arch Ophthalmol 2008; 126(12): 1707-15.
28. Jax TW. Metabolic memory: a vascular perspective. Cardiovasc Diabetol 2010; 9: 51.
29. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352(9131): 837-53.
30. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000; 23(Suppl 2): B21-9.
31. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358(24): 2560-72.
32. Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010; 376(9739): 419-30.
33. Chew EY, Ambrosius WT, Davis MD, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010; 363(3): 233-44.
34. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360(2): 129-39.
35. Riddle MC, Ambrosius WT, Brillon DJ, et al. Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care 2010; 33(5): 983-90.
36. Jenny-Avital ER. Intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359(14): 1519; author reply 20-1.
37. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356(24): 2457-71.
38. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007; 298(10): 1189-95.
39. Wong TY, Mitchell P. Hypertensive retinopathy. N Engl J Med 2004; 351(22): 2310-7.
40. Krolewski AS, Warram JH, Cupples A, et al. Hypertension, orthostatic hypotension and the microvascular complications of diabetes. J Chronic Dis 1985; 38(4): 319-26.
41. Klein BE, Klein R, Moss SE, Palta M. A cohort study of the relationship of diabetic retinopathy to blood pressure. Arch Ophthalmol 1995; 113(5): 601-6.
42. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331(22): 1480-7.
43. Hsueh WA, Anderson PW. Hypertension, the endothelial cell, and the vascular complications of diabetes mellitus. Hypertension 1992; 20(2): 253-63.
44. Agardh CD, Agardh E, Torffvit O. The association between retinopathy, nephropathy, cardiovascular disease and long-term metabolic control in type 1 diabetes mellitus: a 5 year follow-up study of 442 adult patients in routine care. Diabetes Res Clin Pract 1997; 35(2-3): 113-21.
45. Roy R, Jain M, Maheshwari S, Goyal RK. Insulin secretory response in healthy adult offspring of hypertensive parents. J Assoc Physicians India 2000; 48(2): 207-9.
46. Le Floch JP, Christin S, Bertherat J, Perlemuter L, Hazard J. Blood pressure and microvascular complications in type 1 (insulin de pendent) diabetic patients without hypertension. Diabetes Metab 1990; 16(1): 26-9.
47. Cignarelli M, De Cicco ML, Damato A, et al. High systolic blood pressure increases prevalence and severity of retinopathy in NIDDM patients. Diabetes Care 1992; 15(8): 1002-8.
48. Wan Nazaimoon WM, Letchuman R, Noraini N, et al. Systolic hypertension and duration of diabetes mellitus are important determinants of retinopathy and microalbuminuria in young diabetics. Diabetes Res Clin Pract 1999; 46(3): 213-21.
49. Bhuripanyo P, Graisopa S, Suwanwatana C, et al. Vascular complications in noninsulin dependent diabetes mellitus (NIDDM) in Srinagarind Hospital, Khon Kaen. J Med Assoc Thai 1992; 75(10): 570-7.
50. Kostraba JN, Klein R, Dorman JS, et al. The epidemiology of diabetes complications study. IV. Correlates of diabetic background and proliferative retinopathy. Am J Epidemiol 1991; 133(4): 381-91.
51. Chase HP, Garg SK, Jackson WE, et al. Blood pressure and retinopathy in type I diabetes. Ophthalmology 1990; 97(2): 155-9.
52. Rand LI, Krolewski AS, Aiello LM, et al. Multiple factors in the prediction of risk of proliferative diabetic retinopathy. N Engl J Med 1985; 313(23): 1433-8.
53. Knowler WC, Bennett PH, Ballintine EJ. Increased incidence of retinopathy in diabetics with elevated blood pressure. A six-year follow-up study in Pima Indians. N Engl J Med 1980; 302(12): 645-50.
54. Lee ET, Lee VS, Kingsley RM, et al. Diabetic retinopathy in Oklahoma Indians with NIDDM. Incidence and risk factors. Diabetes Care 1992; 15(11): 1620-7.
55. Franklin SS. Arterial siffness and diastolic blood pressure: what is the connection? Artery Res 2006; 1: 6.
56. Chrysant SG, Chrysant GS. Effectiveness of lowering blood pressure to prevent stroke versus to prevent coronary events. Am J Cardiol 2010; 106(6): 825-9.
57. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 1998; 105(10): 1801-15.
58. The Diabetes Drafting Group. Prevalence of small vessel and large vessel disease in diabetic patients from 14 centres. The World Health Organisation Multinational Study of Vascular Disease in Diabetics. Diabetologia 1985; 28 (Suppl): 615-40.
59. Marshall G, Garg SK, Jackson WE, Holmes DL, Chase HP. Factors influencing the onset and progression of diabetic retinopathy in subjects with insulin-dependent diabetes mellitus. Ophthalmology 1993; 100(8): 1133-9.
60. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317(7160): 703-13.
61. Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321(7258):412-9.
62. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology 2008; 115(11): 1859-68.
63. Matthews DR, Stratton IM, Aldington SJ, Holman RR, Kohner EM. Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69. Arch Ophthalmol 2004; 122(11): 1631-40.
64. Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR. Longterm follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 2008; 359(15): 1565-76.
65. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000; 23(Suppl 2): B54-64.
66. Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362(17): 1575-85.
67. Klein R, Moss SE, Klein BE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: VIII. The incidence of retinal photocoagulation. J Diabetes Complications 1988; 2(2): 79-87.
68. van Leiden HA, Dekker JM, Moll AC, et al. Blood pressure, lipids, and obesity are associated with retinopathy: the hoorn study. Diabetes Care 2002; 25(8): 1320-5.
69. Klein R, Moss SE, Klein BE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. XI. The incidence of macular edema. Ophthalmology 1989; 96(10): 1501-10.
70. Klein BE, Klein R, Moss SE. Is serum cholesterol associated with progression of diabetic retinopathy or macular edema in persons with younger-onset diabetes of long duration? Am J Ophthalmol 1999; 128(5): 652-4.
71. Ferris FL, 3rd, Chew EY, Hoogwerf BJ. Serum lipids and diabetic retinopathy. Early Treatment Diabetic Retinopathy Study Research Group. Diabetes Care 1996; 19(11): 1291-3.
72. Cusick M, Chew EY, Chan CC, et al. Histopathology and regression of retinal hard exudates in diabetic retinopathy after reduction of elevated serum lipid levels. Ophthalmology 2003; 110(11): 2126-33.
73. Gupta A, Gupta V, Thapar S, Bhansali A. Lipid-lowering drug atorvastatin as an adjunct in the management of diabetic macular edema. Am J Ophthalmol 2004; 137(4): 675-82.
74. Baghdasarian SB, Jneid H, Hoogwerf BJ. Association of dyslipidemia and effects of statins on nonmacrovascular diseases. Clin Ther 2004; 26(3): 337-51.
75. Sigurdsson R, Begg IS. Organised macular plaques in exudative diabetic maculopathy. Br J Ophthalmol 1980; 64(6): 392-7.
76. Gordon B, Chang S, Kavanagh M, et al. The effects of lipid lowering on diabetic retinopathy. Am J Ophthalmol 1991; 112(4): 385-91.
77. Klein BE, Moss SE, Klein R, Surawicz TS. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XIII. Relationship of serum cholesterol to retinopathy and hard exudate. Ophthalmology 1991; 98(8): 1261-5.
78. De la Cruz JP, Moreno A, Munoz M, Garcia Campos JM, Sanchez de la Cuesta F. Effect of aspirin plus dipyridamole on the retinal vascular pattern in experimental diabetes mellitus. J Pharmacol Exp Ther 1997; 280(1): 454-9.
79. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364(9435): 685-96.
80. Backes JM, Gibson CA, Ruisinger JF, Moriarty PM. Fibrates: what have we learned in the past 40 years? Pharmacotherapy 2007; 27(3): 412-24.
81. Arakawa R, Tamehiro N, Nishimaki-Mogami T, Ueda K, Yokoyama S. Fenofibric acid, an active form of fenofibrate, increases apolipoprotein A-I-mediated high-density lipoprotein biogenesis by enhancing transcription of ATP-binding cassette transporter A1 gene in a liver X receptor-dependent manner. Arterioscler Thromb Vasc Biol 2005; 25(6): 1193-7.
82. Fruchart JC, Duriez P. Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. Drugs Today (Barc) 2006; 42(1): 39-64.
83. Rosenson RS. Fenofibrate: treatment of hyperlipidemia and beyond. Expert Rev Cardiovasc Ther 2008; 6(10): 1319-30.
84. Keech AC, Mitchell P, Summanen PA, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007; 370(9600): 1687-97.
85. Sacks FM. After the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: implications for fenofibrate. Am J Cardiol 2008; 102(12A): 34L-40L.
86. Chew EY, Ambrosius WT, Howard LT, et al. Rationale, design, and methods of the Action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORD-EYE). Am J Cardiol 2007; 99(12A): 103i-11i.
87. Anderson S, Jung FF, Ingelfinger JR. Renal renin-angiotensin system in diabetes: functional, immunohistochemical, and molecular biological correlations. Am J Physiol 1993; 265(4 Pt 2): F477-86.
88. Dzau VJ. Implications of local angiotensin production in cardiovascular physiology and pharmacology. Am J Cardiol 1987; 59(2): 59A-65A.
89. Ritz E, Haxsen V. Angiotensin II and oxidative stress: an unholy alliance. J Am Soc Nephrol 2003; 14(11): 2985-7.
90. Newton CR, Curran B, Victorino GP. Angiotensin II type 1 receptor activation increases microvascular hydraulic permeability. Surgery 2004; 136(5): 1054-60.
91. Newton CR, Curran B, Victorino GP. Angiotensin II type 2 receptor effect on microvascular hydraulic permeability. J Surg Res 2004; 120(1): 83-8.
92. Aguilera G, Kiss A. Regulation of the hypothalmic-pituitaryadrenal axis and vasopressin secretion. Role of angiotensin II. Adv Exp Med Biol 1996; 396: 105-12.
93. Nadal JA, Scicli GM, Carbini LA, Scicli AG. Angiotensin II stimulates migration of retinal microvascular pericytes: involvement of TGF-beta and PDGF-BB. Am J Physiol Heart Circ Physiol 2002; 282(2): H739-48.
94. Hogeboom van Buggenum IM, Polak BC, Reichert-Thoen JW, et al. Angiotensin converting enzyme inhibiting therapy is associated with lower vitreous vascular endothelial growth factor concentrations in patients with proliferative diabetic retinopathy. Diabetologia 2002; 45(2): 203-9.
95. Clermont A, Bursell SE, Feener EP. Role of the angiotensin II type 1 receptor in the pathogenesis of diabetic retinopathy: effects of blood pressure control and beyond. J Hypertens Suppl 2006; 24(1): S73-80.
96. Wu LL, Cox A, Roe CJ, et al. Transforming growth factor beta 1 and renal injury following subtotal nephrectomy in the rat: role of the renin-angiotensin system. Kidney Int 1997; 51(5): 1553-67.
97. Ljubimov AV, Burgeson RE, Butkowski RJ, et al. Basement membrane abnormalities in human eyes with diabetic retinopathy. J Histochem Cytochem 1996; 44(12): 1469-79.
98. Jeganathan VS. The therapeutic implications of renin-angiotensin system blockade in diabetic retinopathy. Curr Pharm Biotechnol 2011; 12(3): 392-5.
99. Steckelings UM, Rompe F, Kaschina E, Unger T. The evolving story of the RAAS in hypertension, diabetes and CV disease: moving from macrovascular to microvascular targets. Fundam Clin Pharmacol 2009; 23(6): 693-703.
100. Sjolie AK. Prospects for angiotensin receptor blockers in diabetic retinopathy. Diabetes Res Clin Pract 2007; 76(Suppl 1): S31-9.
101. Zhang SX, Wang JJ, Gao G, Parke K, Ma JX. Pigment epitheliumderived factor downregulates vascular endothelial growth factor (VEGF) expression and inhibits VEGF-VEGF receptor 2 binding in diabetic retinopathy. J Mol Endocrinol 2006; 37(1): 1-12.
102. Gao BB, Phipps JA, Bursell D, Clermont AC, Feener EP. Angiotensin AT1 receptor antagonism ameliorates murine retinal proteome changes induced by diabetes. J Proteome Res 2009; 8(12): 5541-9.
103. Chaturvedi N, Sjolie AK, Stephenson JM, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 1998; 351(9095): 28-31.
104. Chaturvedi N, Porta M, Klein R, et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebocontrolled trials. Lancet 2008; 372(9647): 1394-402.
105. Sjolie AK, Porta M, Parving HH, Bilous R, Klein R. The DIabetic REtinopathy Candesartan Trials (DIRECT) Programme: baseline characteristics. J Renin Angiotensin Aldosterone Syst 2005; 6(1): 25-32.
106. Mauer M, Zinman B, Gardiner R, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009; 361(1): 40-51.
107. Ruggenenti P, Perna A, Ganeva M, Ene-Iordache B, Remuzzi G. Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial. J Am Soc Nephrol 2006; 17(12): 3472-81.
108. Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370(9590): 829-40.
109. Sjolie AK, Klein R, Porta M, et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECTProtect 2): a randomised placebo-controlled trial. Lancet 2008; 372(9647): 1385-93.
110. Ruggenenti P, Iliev I, Filipponi M, et al. Effect of trandolapril on regression of retinopathy in hypertensive patients with type 2 diabetes: a prespecified analysis of the benedict trial. J Ophthalmol 2010; 2010: 106384.
111. Ruggenenti P, Remuzzi G. Primary prevention of renal failure in diabetic patients: the Bergamo Nephrologic Diabetes Complication Trial. J Hypertens Suppl 1998; 16(1): S95-7.
112. Tolentino MJ, McLeod DS, Taomoto M, et al. Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. Am J Ophthalmol 2002; 133(3): 373-85.
113. Gilbert RE, Kelly DJ, Cox AJ, et al. Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes. Diabetologia 2000; 43(11): 1360-7.
114. Moravski CJ, Skinner SL, Stubbs AJ, et al. The renin-angiotensin system influences ocular endothelial cell proliferation in diabetes: transgenic and interventional studies. Am J Pathol 2003; 162(1): 151-60.
115. Sarlos S, Rizkalla B, Moravski CJ, et al. Retinal angiogenesis is mediated by an interaction between the angiotensin type 2 receptor, VEGF, and angiopoietin. Am J Pathol 2003; 163(3): 879-87.
116. Adamis AP, Miller JW, Bernal MT, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994; 118(4): 445-50.
117. Adamis AP, Altaweel M, Bressler NM, et al. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 2006; 113(1): 23-8.
118. Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008; 300(19): 2277-85.
119. Chou E, Suzuma I, Way KJ, et al. Decreased cardiac expression of vascular endothelial growth factor and its receptors in insulinresistant and diabetic States: a possible explanation for impaired collateral formation in cardiac tissue. Circulation 2002; 105(3): 373-9.
120. Ishida S, Usui T, Yamashiro K, et al. VEGF164 is proinflammatory in the diabetic retina. Invest Ophthalmol Vis Sci 2003; 44(5): 2155-62.
121. Cunningham ET, Jr., Adamis AP, Altaweel M, et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005; 112(10): 1747-57.
122. Hernandez C, Simo R. Strategies for blocking angiogenesis in diabetic retinopathy: from basic science to clinical practice. Expert Opin Investig Drugs 2007; 16(8): 1209-26.
123. Kumar A, Sinha S. Intravitreal bevacizumab (Avastin) treatment of diffuse diabetic macular edema in an Indian population. Indian J Ophthalmol 2007; 55(6): 451-5.
124. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355(14): 1419-31.
125. Heier JS, Boyer DS, Ciulla TA, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol 2006; 124(11): 1532-42.
126. Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12- month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 2010; 33(11): 2399-405.
127. Ladas ID, Karagiannis DA, Rouvas AA, et al. Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2,000 injections. Retina 2009; 29(3): 313-8.
128. RESTORE Study Group. Ranibizumab Alone or Adjunctive to Laser vs Laser Monotherapy in Diabetic Macular Edema: Twelve-Month Results of the RESTORE Study. Annual Meeting of the American Academy of Ophthalmology; Chicago, USA 2010.
129. [129] Salam A, Mathew R, Sivaprasad S. Treatment of proliferative diabetic retinopathy with anti-VEGF agents. Acta Ophthalmol 2011; [Epub ahead of print]
130. Powell ED, Field RA. Diabetic Retinopathy and Rheumatoid Arthritis. Lancet 1964; 2(7349): 17-8.
131. Carroll WW, Geeraets WJ. Diabetic retinopathy and salicylates. Ann Ophthalmol 1972; 4(12): 1019-45.
132. Kern TS, Engerman RL. Pharmacological inhibition of diabetic retinopathy: aminoguanidine and aspirin. Diabetes 2001; 50(7): 1636-42.
133. Zheng L, Howell SJ, Hatala DA, Huang K, Kern TS. Salicylatebased anti-inflammatory drugs inhibit the early lesion of diabetic retinopathy. Diabetes 2007; 56(2): 337-45.
134. The DAMAD Study Group. Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy. A multicenter randomized controlled clinical trial. Diabetes 1989; 38(4): 491-8.